Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Duolingo Inc (DUOL) Price & Performance

ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.

Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.

Duolingo (DUOL) trades at $131.95, up 4.92% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional fundamental strength with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a 38.4% margin. Recent earnings beats and expanding profitability highlight operational excellence amid AI-driven product expansion into math and music learning.

Outlook remains positive with projected 2026 revenue growth to $1.1 billion, though the stock trades above analyst consensus target of $110.20. Key risks include competitive pressure in edtech and valuation concerns with P/E of 14.8 and P/S of 5.7. Institutional sentiment leans cautious with 59% hold ratings despite strong fundamentals.